The purpose of this Paul Calabresi Award in Clinical Oncology Research (PCACOR) is to prepare highly qualified cancer clinical researchers called Scholars who can independently design, manage and complete cancer clinical trials by learning to communicate and coordinate with multidisciplinary teams of clinical and basic scientists using state-of-the-art laboratory analyses to personalize cancer treatment. Specific objectives are to: 1) Provide a flexible Individual Development Program for oncology medical doctors and Ph.D. clinicians (nurses, pharmacists, clinical psychologists, epidemiologists, oral surgeons) who have completed their clinical training and basic research scientists who are committed to a translational clinical cancer research career in an academic setting;2) Foster interdisciplinary training, communication and interaction through multiple mentoring of program scholars;3) Create an ongoing mentorship to the completed PCACOR Scholars to ensure their successful transition to clinical research independence. Strong clinical and basic science mentors provide exceptional training and role models in all oncology clinical disciplines as well in cancer basic science. A multidisciplinary Advisory Committee oversees the PCACOR directed by Program Leaders, Madeleine A. Kane, MD, Ph.D., Professor of Medical Oncology, and Andrew Thorburn, Ph.D., Professor and Chair, Department of Pharmacology, Deputy Director, UCCC. Training period lasts from two to seven years and includes Core requirements such as Responsible Conduct of Research and coursework provided by CCTSI Clinical Science Program and the UCD Graduate School. Each Scholar completes a basic science project and also designs at least one cancer clinical trial. Scholars submit an NIH style grant application within the last yea of training. The ultimate success is demonstrated by our track record. A total of fifteen junior faculty have trained as PCACOR Scholars, nine during the current funding period (out of 42 applications). Thirteen Scholars remain faculty members at University of Colorado Denver Anschutz Medical Campus (UCD-AMC);six have been promoted, all have multiple peer-reviewed publications, both clinical and basic science. Eight have obtained peer-reviewed funding from NIH, DOD ACS and/or Komen Foundation. All have designed at least one cancer clinical trial, and several PCACOR graduates lead national cancer clinical trials, cancer research training programs and clinical cancer research programs. Our PCACOR successfully produces the translational cancer clinical researchers of the future.

Public Health Relevance

The Paul Calabresi Award for Clinical Oncology Research trains translational clinical and basic cancer researchers who can work together to combine molecular methods with clinical information to personalize cancer clinical trials to improve the outcome for cancer patients with less toxicity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA086913-13
Application #
8701241
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
2000-09-18
Project End
2018-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
13
Fiscal Year
2014
Total Cost
$1,072,522
Indirect Cost
$81,319
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Kiseljak-Vassiliades, Katja; Zhang, Yu; Bagby, Stacey M et al. (2018) Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer 25:437-451
Courtney, Kevin D; Infante, Jeffrey R; Lam, Elaine T et al. (2018) Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2? Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. J Clin Oncol 36:867-874
Lam, Elaine T; Eckhardt, S Gail; Messersmith, Wells et al. (2018) Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors. Mol Cancer Ther 17:215-221
Kessler, Elizabeth R; Su, Lih-Jen; Gao, Dexiang et al. (2018) Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. Integr Cancer Ther 17:1103-1108
Bhatia, Shilpa; Griego, Anastacia; Lennon, Shelby et al. (2018) Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor. Mol Cancer Ther 17:2049-2059
Kessler, E R; Gao, D; Flaig, T W et al. (2017) Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate. Ann Oncol 28:668
Campbell, Warren G; Jones, Bernard L; Schefter, Tracey et al. (2017) An evaluation of motion mitigation techniques for pancreatic SBRT. Radiother Oncol 124:168-173
Dorris, Kathleen; Liu, Chunyan; Li, Dandan et al. (2017) A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials. Pediatr Blood Cancer 64:
Carrasco Jr, Alonso; Caldwell, Brian T; Cost, Carrye R et al. (2017) Reliability of intraoperative frozen section for the diagnosis of renal tumors suspicious for malignancy in children and adolescents. Pediatr Blood Cancer 64:
Campbell, Warren G; Miften, Moyed; Olsen, Lindsey et al. (2017) Neural network dose models for knowledge-based planning in pancreatic SBRT. Med Phys 44:6148-6158

Showing the most recent 10 out of 100 publications